Amplia Therapeutics (Amplia Therapeutics) FCF Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Amplia Therapeutics's Free Cash Flow for the six months ended in Sep. 2023 was $-2.28 Mil. Amplia Therapeutics's Revenue for the six months ended in Sep. 2023 was $0.00 Mil. Therefore, Amplia Therapeutics's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Amplia Therapeutics's current FCF Yield % is -50.69%.

The historical rank and industry rank for Amplia Therapeutics's FCF Margin % or its related term are showing as below:

During the past 10 years, the highest FCF Margin % of Amplia Therapeutics was -13343.33%. The lowest was -13343.33%. And the median was -13343.33%.

INNMF's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -141.21
* Ranked among companies with meaningful FCF Margin % only.

Amplia Therapeutics FCF Margin % Historical Data

The historical data trend for Amplia Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics FCF Margin % Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amplia Therapeutics's FCF Margin %

For the Biotechnology subindustry, Amplia Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's FCF Margin % falls into.

Amplia Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Amplia Therapeutics's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-3.543	/	0
	=	%

Amplia Therapeutics's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-2.277	/	0
	=	%

Amplia Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024